Skip to Content
  • Previous Rank
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees
  • Market Value — as of March 29, 2018 ($M)

The Pennsylvania-based drug distributor saw revenues grow in 2017 thanks to increased business from some of its largest customers and strong sales of expensive cancer drugs. Amerisources’s animal health unit, MWI, also recorded strong sales growth thanks to its brisk pet medicine business. Profits took a hit due to accrued litigation costs from the previous year. Like other large drug distributors, Amerisource faces a number of lawsuits over its alleged role in the nation’s opioid epidemic.

Company Info

Figures are for fiscal year ended Sept. 30, 2017.
Steven H. Collis
CEO Title
Chairman, President & Chief Executive Officer
Wholesalers: Health Care
HQ Location
Chesterbrook, Pa.
Years on Fortune 500 List24
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

AmerisourceBergen Rank History


Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$153,143.804.3%
Profits ($M)$364.5-74.5%
Assets ($M)$35,316.50-
Total Stockholder Equity ($M)$2,064.50-
Market Value — as of March 29, 2018 ($M)$18,937.70-

Profit Ratios

Profit as % of Revenues0.2%
Profits as % of Assets1%
Profits as % of Stockholder Equity17.7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1.64
EPS % Change (from 2016)-74.1%
EPS % Change (5 year annual rate)-10.1%
EPS % Change (10 year annual rate)2.8%

Total Return

Total Return to Investors (2017)19.4%
Total Return to Investors (5 year, annualized)18%
Total Return to Investors (10 year, annualized)16.6%